Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors

F. Janku; R. Abdul-Karim; A. Azad; J. Bendell; H. Gan; S. Sen; T. Tan; J. Wang; N. Marina; L. Baker; L. Ma; J. Mooney; D. Luo; J. Leveque; M. Milla; Tarek Meniawy

doi:10.1016/S0959-8049(20)31094-7

Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors

F. Janku, R. Abdul-Karim, A. Azad, J. Bendell, H. Gan, S. Sen, T. Tan, J. Wang, N. Marina, L. Baker, L. Ma, J. Mooney, D. Luo, J. Leveque, M. Milla, Tarek Meniawy

Internal Medicine

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

1 Citation (Web of Science)

Original language	English
Pages (from-to)	S11-S11
Number of pages	1
Journal	European Journal of Cancer
Volume	138
DOIs	https://doi.org/10.1016/S0959-8049(20)31094-7
Publication status	Published - Oct 2020
Event	32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Duration: 24 Oct 2020 → 25 Oct 2020

Access to Document

10.1016/S0959-8049(20)31094-7

Cite this

Janku, F., Abdul-Karim, R., Azad, A., Bendell, J., Gan, H., Sen, S., Tan, T., Wang, J., Marina, N., Baker, L., Ma, L., Mooney, J., Luo, D., Leveque, J., Milla, M., & Meniawy, T. (2020). Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors. European Journal of Cancer, 138, S11-S11. https://doi.org/10.1016/S0959-8049(20)31094-7

@article{7accfdef9e764647ad6f8f8752b5fbc5,

title = "Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors",

author = "F. Janku and R. Abdul-Karim and A. Azad and J. Bendell and H. Gan and S. Sen and T. Tan and J. Wang and N. Marina and L. Baker and L. Ma and J. Mooney and D. Luo and J. Leveque and M. Milla and Tarek Meniawy",

year = "2020",

month = oct,

doi = "10.1016/S0959-8049(20)31094-7",

language = "English",

volume = "138",

pages = "S11--S11",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier",

note = "32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics ; Conference date: 24-10-2020 Through 25-10-2020",

}

Janku, F, Abdul-Karim, R, Azad, A, Bendell, J, Gan, H, Sen, S, Tan, T, Wang, J, Marina, N, Baker, L, Ma, L, Mooney, J, Luo, D, Leveque, J, Milla, M & Meniawy, T 2020, 'Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors', European Journal of Cancer, vol. 138, pp. S11-S11. https://doi.org/10.1016/S0959-8049(20)31094-7

Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors. / Janku, F.; Abdul-Karim, R.; Azad, A. et al.
In: European Journal of Cancer, Vol. 138, 10.2020, p. S11-S11.

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

TY - JOUR

T1 - Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors

AU - Janku, F.

AU - Abdul-Karim, R.

AU - Azad, A.

AU - Bendell, J.

AU - Gan, H.

AU - Sen, S.

AU - Tan, T.

AU - Wang, J.

AU - Marina, N.

AU - Baker, L.

AU - Ma, L.

AU - Mooney, J.

AU - Luo, D.

AU - Leveque, J.

AU - Milla, M.

AU - Meniawy, Tarek

PY - 2020/10

Y1 - 2020/10

U2 - 10.1016/S0959-8049(20)31094-7

DO - 10.1016/S0959-8049(20)31094-7

M3 - Abstract/Meeting Abstract

SN - 0959-8049

VL - 138

SP - S11-S11

JO - European Journal of Cancer

JF - European Journal of Cancer

T2 - 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Y2 - 24 October 2020 through 25 October 2020

ER -